Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;30(4):417-24.
doi: 10.1055/s-0033-1359738.

Gynecologic biopsy for molecular profiling: a review for the interventional radiologist

Bradley R Corr  1 , Kian Behbakht  1 , Monique A Spillman  1
Affiliations
Review

Gynecologic biopsy for molecular profiling: a review for the interventional radiologist

Bradley R Corr et al. Semin Intervent Radiol. 2013 Dec.

Abstract

The interventional radiologist is often asked to obtain multiple biopsies of gynecological malignancies for genetic profiling. This article reviews the current indications for gynecological biopsy as well as how the information gained contributes to a personalized medicine plan for the individual patient. The specific focus of this review is the current knowledge and practice of molecular profiling for gynecological malignancies.

Keywords: biopsy; genetic profiling; gynecological cancer; interventional radiology; molecular profiling.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Howlader N NA Krapcho M Garshell J et al.SEER Cancer Statistics Review, 1975–2010 Bethesda, MD: National Cancer Institute; 2013; Based on November 2012 SEER data submission, posted to the SEER Web site http://seer.cancer.gov/csr/1975_2010/
    1. Cannistra S A. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. - PubMed
    1. Parmar M K, Ledermann J A, Colombo N. et al.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–2106. - PubMed
    1. Morgan R J Jr Copeland L Gershenson D et al.NCCN Ovarian Cancer Practice Guidelines Oncology (Williston Park) 199610(11, Suppl):293–310. - PubMed